Abstract
Gamma irradiation (GI) is included in the CDC guidance on inactivation procedures to render a group of select agents and toxins nonviable. The Ebola virus falls within this group because it potentially poses a severe threat to public health and safety. To evaluate the impact of GI at a target dose of 50 kGy on neutralizing antibody titers induced by the rVSVΔG-ZEBOV-GP vaccine (V920), we constructed a panel of 48 paired human serum samples (GI-treated versus non-GI-treated) from healthy participants selected from a phase 3 study of V920 (study V920-012; NCT02503202). Neutralizing antibody titers were determined using a validated plaque-reduction neutralization test. GI of sera from V920 recipients was associated with approximately 20% reduction in postvaccination neutralizing antibody titers. GI was not associated with any change in pre-vaccination neutralizing antibody titers.
Publication types
-
Research Support, Non-U.S. Gov't
-
Research Support, U.S. Gov't, Non-P.H.S.
MeSH terms
-
Antibodies, Neutralizing / analysis
-
Antibodies, Neutralizing / blood*
-
Antibodies, Viral / blood*
-
Ebola Vaccines / administration & dosage*
-
Ebola Vaccines / chemical synthesis
-
Ebolavirus / immunology*
-
Ebolavirus / pathogenicity
-
Healthy Volunteers
-
Hemorrhagic Fever, Ebola / blood
-
Hemorrhagic Fever, Ebola / immunology
-
Hemorrhagic Fever, Ebola / prevention & control*
-
Hemorrhagic Fever, Ebola / virology
-
Humans
-
Immune Sera / chemistry
-
Immune Sera / radiation effects*
-
Immunogenicity, Vaccine
-
Neutralization Tests
-
Prospective Studies
-
Vaccination / methods
-
Vesiculovirus / chemistry
-
Vesiculovirus / immunology
-
Viral Envelope Proteins / immunology
Substances
-
Antibodies, Neutralizing
-
Antibodies, Viral
-
Ebola Vaccines
-
Immune Sera
-
Viral Envelope Proteins
-
envelope glycoprotein, Ebola virus
Associated data
-
ClinicalTrials.gov/NCT02503202